A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 1000
- Registration Number
- NCT05862272
- Locations
- 🇺🇸
Mesa, Mesa, Arizona, United States
🇺🇸Erie, Erie, Pennsylvania, United States
🇺🇸Meridian, Meridian, Idaho, United States
MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 530
- Registration Number
- NCT05739136
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 728
- Registration Number
- NCT05739123
- Locations
- 🇺🇸
PPD, Wilmington, North Carolina, United States
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
- Conditions
- Interventions
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 2250
- Registration Number
- NCT05605964
- Locations
- 🇺🇸
Lowcountry Urology Clinics, North Charleston, South Carolina, United States
🇺🇸NorthShore University Health System - Glenbrook Hospital Ambulatory Care Center Satellite, Glenview, Illinois, United States
🇺🇸SG Research LLC, Miami, Florida, United States
A Multi-Center, Prospective, Observational Study of Patients Being Treated with ORGOVYX
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 999
- Registration Number
- NCT05467176
- Locations
- 🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸Ascend Pharma Holdings, Houston, Texas, United States
Congenital Athymia Patient Registry
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 75
- Registration Number
- NCT05329935
- Locations
- 🇺🇸
Duke University School of Medicine, Durham, North Carolina, United States
Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 1020
- Registration Number
- NCT04756037
- Locations
- 🇺🇸
Aventura, Aventura, Florida, United States
🇺🇸Burbank, Burbank, California, United States
🇺🇸Norcross, Norcross, Georgia, United States
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT04666129
- Locations
- 🇺🇸
Clinical Research Alliance, Inc., Westbury, New York, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸Alliance Urology, Greensboro, North Carolina, United States
Farber Disease Natural History Study
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 45
- Registration Number
- NCT03233841
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸Children's National Health System, Washington, District of Columbia, United States
🇦🇷Hospital de Niños de la Santisima Trinidad, Córdoba, CP, Argentina
Expanded Access Protocol Thymus Transplantation
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 11
- Registration Number
- NCT02274662